Month: September 2026

Conference Call Scheduled for Today, September 28, 2026, at 5:00 p.m. ET

LITTLETON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) — Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced financial results for its fourth quarter and fiscal year ended June 30, 2026.

Q4 2026 Financial Highlights (3 Months Ended June 30, 2026)

• Revenue was $8.8 million, a quarterly record, compared to $6.2 million in the same quarter of the previous fiscal year, representing growth of approximately 42%, and compared to $8.7 million in the most recent sequential quarter.
• Production revenue was $8.0 million, a quarterly record, compared to $5.1 million in the same quarter of the previous fiscal year, representing growth of approximately 57%, and compared to $7.6 million in the most recent sequential quarter.
• Gross margin was 25.3% compared to 13.0% in the same quarter of the previous fiscal year and compared to 23.6% in the most recent sequential quarter.
• Net loss for the quarter was $(0.1) million, compared to a net loss of $(1.4) million in the same quarter of the previous fiscal year and a net loss of $(0.1) million in the most recent sequential quarter.
• Adjusted EBITDA was $0.4 million for the quarter compared to $(0.9) million in the same quarter of the previous fiscal year and $0.3 million in the most recent sequential quarter.

FY 2026 Financial Highlights (Year Ended June 30, 2026)

• Revenue was $31.5 million, a fiscal year record, compared to $19.1 million in the previous fiscal year, representing growth of approximately 65%.
• Production revenue doubled to $28.1 million compared to $14.2 million in the previous fiscal year.
• Gross margin was 17.2% compared to 17.8% in the previous fiscal year.
• Net loss for the fiscal year declined to $(3.6) million, or $(0.43) per share, from $(5.8) million, or $(0.85) per share, in the previous fiscal year.
• Adjusted EBITDA was $(2.1) million for the fiscal year compared to $(3.7) million in the previous fiscal year, an improvement of approximately $1.6 million.
• Cash and cash equivalents were $9.8 million at June 30, 2026, compared to $1.8 million at June 30, 2025.

Recent Additional Highlights

• Achieved record quarterly revenue from the Company’s existing top-tier aerospace customer and continued strong production of its single-use cystoscopy surgery system.
• Continued ramping production under the previously announced $3.5 million follow-on order for the single-use ophthalmic program.
• Received a $1.3 million follow-on production order from a large defense company.
• Recently announced an initial engineering order from a U.S. space technology company.
• Continued strengthening the Company’s leadership team with the appointment of Peter Thier as Senior Vice President of Sales and Marketing.

FY 2027 Financial Guidance (Year Ending June 30, 2027)

• The Company expects fiscal year 2027 revenue to be in the range of $30 million to $33 million, similar to fiscal year 2026. The outlook reflects a pause in demand from the Company’s existing satellite customer with growth in single-use medical device programs, renewed defense production, additional programs transitioning into production and new engineering engagements expecting to partly offset this reduction. The Company expects a stronger second half of the year as orders are expected to resume from the existing satellite customer.
• The Company expects fiscal year 2027 Adjusted EBITDA to be in a range of $(1.2) million to $(1.7) million.

“Fiscal 2026 was a year of transformation for Precision Optics, and our fourth-quarter results demonstrate the progress we have made. We delivered record quarterly revenue, and a second consecutive quarter of positive Adjusted EBITDA, closing a year in which revenue grew 65%,” said Joe Forkey, CEO of Precision Optics. “Our fiscal 2027 revenue guidance is significantly impacted by the temporary pause in production with our existing satellite customer. As that customer resumes orders and we execute on growing existing and new customers, we anticipate returning to record quarterly revenue levels in the second half of the fiscal year. We believe there is a significant market opportunity, and we will continue to invest in capabilities, capacity and market penetration.”

“Rebuilding our product development pipeline is a priority led by our new SVP of Sales and Marketing. We received an initial engineering order from a second satellite customer. Although it is still early, we see the potential to build another meaningful, long-term production relationship.”

The following table summarizes the fourth quarter and fiscal year results for the periods ended June 30, 2026 and 2025. Fourth-quarter results are unaudited.

	Three Months Ended June 30 2026	Three Months Ended June 30 2025	Year Ended June 30 2026	Year Ended June 30 2025
Revenues	$8,774,474	$6,181,342	$31,531,765	$19,091,269
Cost of goods sold	6,550,806	5,382,155	26,100,545	15,686,836
Gross profit	2,223,668	799,187	5,431,220	3,404,433
Total operating expenses	2,330,228	2,155,229	8,939,828	8,955,724
Operating income (loss)	(106,560)	(1,356,042)	(3,508,608)	(5,551,291)
Interest income (expense), net	(971)	(44,577)	(116,325)	(227,019)
Income (loss) before income taxes	(107,531)	(1,400,619)	(3,624,933)	(5,778,310)
Income tax expense (benefit)	(3,744)	1,936	4,958	1,936
Net Loss	$(103,787)	$(1,402,555)	$(3,629,891)	$(5,780,246)
Earnings (loss) per share, basic	$(0.01)	$(0.18)	$(0.43)	$(0.85)
Earnings (loss) per share, diluted	$(0.01)	$(0.18)	$(0.43)	$(0.85)
Weighted average shares, basic	10,943,843	7,690,084	8,530,599	6,790,466
Weighted average shares, diluted	10,943,843	7,690,084	8,530,599	6,790,466

Conference Call Details

Date and Time: Monday, September 28, 2026, at 5:00 p.m. ET.

Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or (412) 317-5705.

Live Webcast Information: Interested parties can access the conference call via a live webcast, which will be available at https://app.webinar.net/0E4e7l07PjV.

Replay: A teleconference replay of the call will be available for seven days at (855) 669-9658 or (412) 317-0088, replay access code 7128172. A webcast replay will be available at https://app.webinar.net/0E4e7l07PjV.

About Precision Optics Corporation

Founded in 1982, Precision Optics is a vertically integrated optics company focused on leveraging its proprietary micro-optics, multi-channel and ultra-high precision imaging and digital imaging technologies across the medical device, defense/aerospace and satellite communications markets. Through its Systems Manufacturing, Engineering, Ross Optical and Micro-Optics Lab operations, the Company provides services from new product concept and design through volume production. Its in-house optical, mechanical, electrical and systems engineering, prototyping, regulatory support, fabrication, assembly and manufacturing capabilities enable it to develop next-generation solutions for demanding customer requirements. In medical devices, Precision Optics supports minimally invasive and robotic surgery with micro-endoscopes, single-use and reusable endoscopes, digital imaging and related optical assemblies. In defense/aerospace and satellite communications, the Company applies its micro-optics and opto-mechanical expertise to applications requiring high quality and optimized size, weight and power. Ross Optical complements these capabilities through global sourcing, inspection and production of custom and catalog optics. For more information, please visit www.poci.com.

Non-GAAP Financial Measures

Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). In addition to these items, Adjusted EBITDA excludes from Net Income (Loss) the effect of stock-based compensation, interest expense and interest income, depreciation and amortization and income taxes..

This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.

Precision Optics is unable to provide a reconciliation of forward-looking Adjusted EBITDA guidance to net income (loss), the most directly comparable GAAP financial measure, without unreasonable efforts because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including stock-based compensation expense, which may vary significantly based on stock price and other factors outside the Company’s control. The unavailable information could have a significant effect on the Company’s GAAP financial results.

About Forward-Looking Statements

This press release contains forward-looking statements within the meaning of U.S. federal securities laws including statements concerning our fiscal year 2027 revenue and Adjusted EBITDA guidance, our expectations regarding customer demand and order resumption, and our anticipated return to record revenue levels. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including the demand for the Company’s products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company’s filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

PRECISION OPTICS CORPORATION, INC. Balance Sheets at June 30, 2026 and 2025
		2026				2025
ASSETS
Current Assets:
Cash and cash equivalents		$	9,841,142			$	1,773,735
Accounts receivable, net of allowance for credit losses of $108,220 at June 30, 2026 and $80,192 at June 30, 2025			5,944,412				4,336,730
Inventories, net			3,829,414				3,562,112
Prepaid expenses			494,488				385,390
Total current assets			20,109,456				10,057,967
Fixed Assets:
Machinery and equipment			3,410,813				3,385,958
Leasehold improvements			1,226,171				871,356
Furniture and fixtures			645,046				538,428
			5,282,030				4,795,742
Less—Accumulated depreciation and amortization			4,394,317				4,261,950
Net fixed assets			887,713				533,792
Operating lease right-of-use asset			2,300,866				141,825
Patents, net			212,889				232,493
Goodwill			8,824,210				8,824,210
Total other assets			11,337,965				9,198,528
TOTAL ASSETS		$	32,335,134			$	19,790,287
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Current portion of capital lease obligation		$	–			$	27,368
Current maturities of long-term debt			577,898				577,898
Accounts payable			3,582,674				2,909,100
Customer advances			2,498,501				1,821,929
Accrued compensation and other			1,843,368				764,004
Operating lease liability			325,500				50,995
Total current liabilities			8,827,941				6,151,294
Long-term debt, net of current maturities			711,305				1,289,205
Operating lease liability, net of current portion			2,446,576				90,954
Total liabilities			11,985,822				7,531,453
Stockholders’ Equity:
Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding – 10,972,792 shares at June 30, 2026 and 7,714,701 shares at June 30, 2025			109,728				77,147
Additional paid-in capital			80,840,105				69,152,317
Accumulated deficit			(60,600,521	)			(56,970,630	)
Total stockholders’ equity			20,349,312				12,258,834
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	32,335,134			$	19,790,287

PRECISION OPTICS CORPORATION, INC. Statements of Operations for the Years Ended June 30, 2026 and 2025
		2026				2025
Revenues		$	31,531,765			$	19,091,269
Cost of goods sold			26,100,545				15,686,836
Gross profit			5,431,220				3,404,433
Research and development expenses, net			1,033,156				1,157,963
Selling, general and administrative expenses			7,906,672				7,797,761
Total operating expenses			8,939,828				8,955,724
Operating loss			(3,508,608	)			(5,551,291	)
Other expense
Interest expense			(148,129	)			(227,019	)
Interest income			31,804				–
Loss before provision for income taxes			(3,624,933	)			(5,778,310	)
Provision for income taxes			4,958				1,936
Net loss		$	(3,629,891	)		$	(5,780,246	)
Loss per share:
Basic and fully diluted		$	(0.43	)		$	(0.85	)
Weighted average common shares outstanding:
Basic and fully diluted			8,530,599				6,790,466

PRECISION OPTICS CORPORATION, INC. Statements of Stockholders’ Equity for the Years Ended June 30, 2026 and 2025
		Number of Shares				Common Stock				Additional Paid-in Capital				Accumulated Deficit				Total Stockholders’ Equity
Balance, June 30, 2024			6,073,939			$	60,739			$	61,197,433			$	(51,190,384	)		$	10,067,788
Issuance of common stock in a registered direct offering			1,538,368				15,384				6,254,752				–				6,270,136
Proceeds from exercise of stock option			71,979				721				88,329				–				89,050
Issuance of common stock for consulting services and employees			30,415				303				151,395				–				151,698
Stock-based compensation			–				–				1,460,408				–				1,460,408
Net loss			–				–				–				(5,780,246	)			(5,780,246	)
Balance, June 30, 2025			7,714,701			$	77,147			$	69,152,317			$	(56,970,630	)		$	12,258,834
Issuance of common stock in public offering			3,194,444				31,944				10,598,734				–				10,630,678
Proceeds from exercise of stock option			40,294				404				39,595				–				39,999
Issuance of common stock for employee services			23,353				233				100,267				–				100,500
Stock-based compensation			–				–				949,192				–				949,192
Net loss			–				–				–				(3,629,891	)			(3,629,891	)
Balance, June 30, 2026			10,972,792			$	109,728			$	80,840,105			$	(60,600,521	)		$	20,349,312

PRECISION OPTICS CORPORATION, INC. Statements of Cash Flows For the Years Ended June 30, 2026 and 2025
		2026				2025
Cash Flows from Operating Activities:
Net loss		$	(3,629,891	)		$	(5,780,246	)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities-
Depreciation and amortization			279,277				212,439
Stock-based compensation expense			1,139,692				1,612,106
Non-cash legal expense			–				34,881
Non-cash interest expense			18,433				11,563
Non-cash operating lease expense			252,336				124
Loss on disposal of fixed assets			34,506				–
Changes in operating assets and liabilities:
Accounts receivable, net			(1,607,682	)			(791,239	)
Inventories			(267,302	)			(694,012	)
Prepaid expenses			(109,098	)			(86,026	)
Accounts payable			673,574				1,511,787
Contract liabilities			676,572				649,579
Accrued compensation and other			989,364				(76,658	)
Net cash used in operating activities			(1,550,219	)			(3,395,702	)
Cash Flows from Investing Activities:
Additional patent costs			(5,564	)			(6,264	)
Proceeds from sale of fixed assets			3,000				–
Purchases of property and equipment			(426,786	)			(227,209	)
Net cash used in investing activities			(429,350	)			(233,473	)
Cash Flows from Financing Activities:
Payment of capital lease obligations			(27,368	)			(41,114	)
Principal payments of long-term debt			(596,333	)			(280,440	)
Payment of debt issuance costs			–				(40,000	)
Repayments on line of credit			–				(1,000,000	)
Gross proceeds from registered direct offerings of common stock			–				6,270,136
Proceeds from public offering of common stock, net			10,630,678				–
Gross proceeds from exercise of stock options			39,999				89,050
Net cash provided by financing activities			10,046,976				4,997,632
Net increase in cash and cash equivalents			8,067,407				1,368,457
Cash and cash equivalents, beginning of year			1,773,735				405,278
Cash and cash equivalents, end of year		$	9,841,142			$	1,773,735
Supplemental disclosure of cash flow information:
Cash paid during the year for income taxes		$	2,600			$	1,936
Cash paid during the year for interest		$	129,696			$	216,456
Leasehold improvements financed by landlord		$	218,750			$	–
Issuance of common stock for consulting and employee services		$	100,500			$	151,698
Stock based compensation for employee services included in accrued compensation and other		$	90,000			$	–
Operating right-of-use assets obtained in exchange for operating lease liabilities		$	2,632,584			$	133,650

PRECISION OPTICS CORPORATION, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
ADJUSTED EBITDA
		Three Months Ended								Year Ended
		June 30								June 30
		2026				2025				2026				2025
Net Loss (GAAP)		$	(103,787	)		$	(1,402,555	)		$	(3,629,891	)		$	(5,780,246	)
Stock based compensation			397,193				439,873				1,139,692				1,612,106
Depreciation and amortization			64,329				59,226				279,277				212,439
Income Taxes			(3,744	)			1,936				4,958				1,936
Interest Expense			32,775				44,577				148,129				227,019
Interest Income			(31,804	)			–				(31,804	)			–
Adjusted EBITDA (non-GAAP)		$	354,962			$	(856,943	)		$	(2,089,639	)		$	(3,726,746	)

CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, announced today a net loss of $13.5 million, or ($2.23) per diluted share, on net sales of $34.5 million for the fourth quarter of fiscal year 2026 compared to a net loss of $7.2 million, or ($1.20) per diluted share, in the fourth quarter of the prior fiscal year. Our net loss for the fourth quarter of fiscal 2026 includes a non-recurring non-cash charge of $10.4 million related to the impairment of our Carlsbad, CA manufacturing facility due to its underutilization. Excluding this charge, our net loss for the fourth quarter of fiscal 2026 would have been $3.1 million, or ($0.52) per diluted share.

Net sales during the three months ended June 30, 2026, increased $0.6 million, or 1.9%, to $34.5 million compared to $33.9 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased 0.6% to $31.9 million. Private-label contract manufacturing sales increased primarily due to increased orders from one of our larger customers, partially offset by reduced orders from other existing customers.

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 22% to $2.6 million during the fourth quarter of fiscal year 2026, as compared to $2.1 million for the fourth quarter of fiscal year 2025. The increase in CarnoSyn® beta-alanine royalty, licensing, and raw material sales revenue during the fourth quarter of fiscal 2026 was primarily due to increased raw material sales to existing customers and increased royalty income.

Our net loss for our fiscal year ending June 30, 2026, was $20.7 million, or ($3.43) per diluted share, compared to a net loss of $13.6 million, or ($2.28) per diluted share for fiscal year 2025. Our net loss for fiscal 2026 included the non-recurring, non-cash charge of $10.4 million related to the impairment of our Carlsbad, CA. manufacturing facility, and related assets. Excluding this charge, our net loss for fiscal 2026 would have been $10.3 million or ($1.71) per diluted share.

Net sales during the year ended June 30, 2026, increased $12.7 million, or 10%, to $142.5 million as compared to $129.9 million recorded in the comparable prior year period. During the year ended June 30, 2026, private-label contract manufacturing sales increased 11% to $134.6 million, as compared to $121.8 million in the comparable prior period. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 2% to $7.9 million during fiscal 2026, as compared to $8.1 million for fiscal 2025.

While we grew sales during the three and twelve months ended June 30, 2026, we experienced a net loss primarily due to underutilization of our available factory capacities and a non-cash impairment charge against our Carlsbad, CA manufacturing facility. 

To increase our capacity utilization and reduce operating costs, we have initiated the consolidation of our USA manufacturing operations into our Vista, CA facility, which includes the anticipated sale of our Carlsbad, CA manufacturing facility. We have also initiated a comprehensive review process to explore strategic alternatives focused on maximizing shareholder value including evaluating a full range of strategic growth paths, potential mergers, acquisitions, joint ventures, or a sale of the Company.

As of June 30, 2026, we had cash of $7.5 million and working capital of $27.7 million, compared to $12.3 million and $30.5 million respectively, as of June 30, 2025. As of June 30, 2026, we had $17.7 million of borrowing capacity on our credit facility of which we had outstanding borrowings of $7.7 million.

Mark A. Le Doux, Chairman and Chief Executive Officer of NAI stated, “We are taking decisive steps to strengthen our financial position and better align our operations with current market demand. The planned sales of our Carlsbad, CA Headquarters building and the expected sale of the Carlsbad, CA manufacturing facility are an important part of this effort and are expected to provide additional liquidity, reduce debt, and eliminate significant excess manufacturing capacity. We believe we can successfully consolidate production into our Vista, CA facility without disrupting our customers, while continuing to focus on growing revenue, expanding customer relationships and reducing costs.”

An updated investor presentation will be posted to the investor relations page on our website later today (https://www.nai-online.com/our-company/investors/).

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging, and delivery system design, regulatory review, and international product registration assistance. For more information about NAI, please see our website at http://www.nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our ability to develop, maintain or increase sales to new and existing customers, our future revenue, profits, and financial condition. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

SOURCE – Natural Alternatives International, Inc.

CONTACT – Kenneth Wolf, President, Chief Operating Officer and Acting Principal Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or investor@nai-online.com.

Web site: http://www.nai-online.com

NATURAL ALTERNATIVES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
	(Unaudited)
	Three Months Ended														Year Ended
	June 30,														June 30,
		2026							2025							2026							2025
NET SALES	$	34,508			100.0	%		$	33,866			100.0	%		$	142,515			100.0	%		$	129,860			100.0	%
Cost of goods sold		32,782			95.0	%			30,331			89.6	%			133,518			93.7	%			120,571			92.8	%
Gross profit		1,726			5.0	%			3,535			10.4	%			8,997			6.3	%			9,289			7.2	%
Other selling, general & administrative expenses		4,460			12.9	%			4,079			12.0	%			17,296			12.1	%			16,549			12.7	%
Settlement of legal proceedings & associated expense		32			0.1	%			1,400			4.1	%			44			0.0	%			1,400			1.1	%
Selling, general & administrative expenses		4,492			13.0	%			5,479			16.2	%			17,340			12.2	%			17,949			13.8	%
Impairment loss		10,409			30.2	%										10,409			7.3	%
LOSS FROM OPERATIONS		(13,175	)		-38.2	%			(1,944	)		-5.7	%			(18,752	)		-13.2	%			(8,660	)		-6.7	%
Other expense, net		(319	)		-0.9	%			(875	)		-2.6	%			(1,513	)		-1.1	%			(2,080	)		-1.6	%
LOSS BEFORE TAXES		(13,494	)		-39.1	%			(2,819	)		-8.3	%			(20,265	)		-14.2	%			(10,740	)		-8.3	%
Income tax expense		46							4,397							430							2,835
NET LOSS	$	(13,540	)					$	(7,216	)					$	(20,695	)					$	(13,575	)
NET LOSS PER COMMON SHARE:
Basic:	$	(2.23	)					$	(1.20	)					$	(3.43	)					$	(2.28	)
Diluted:	$	(2.23	)					$	(1.20	)					$	(3.43	)					$	(2.28	)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic		6,071							6,003							6,028							5,947
Diluted		6,071							6,003							6,028							5,947

NATURAL ALTERNATIVES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
	June 30,				June 30,
		2026				2025
ASSETS
Cash and cash equivalents	$	7,388			$	12,325
Restricted cash		86				–
Accounts receivable, net		20,650				14,644
Inventories, net		30,753				24,871
Other current assets		6,557				7,436
Total current assets		65,434				59,276
Property and equipment, net		35,605				50,890
Operating lease right-of-use assets		24,062				41,054
Other noncurrent assets, net		1,345				719
Total Assets	$	126,446			$	151,939
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable and accrued liabilities		26,514				24,483
Line of Credit		7,749				1,900
Mortgage note payable		10,939				8,933
Operating lease liability		31,285				48,197
Total Liabilities		76,487				83,513
Stockholders’ Equity		49,959				68,426
Total Liabilities and Stockholders’ Equity	$	126,446			$	151,939

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman.

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA approval and the launch of Genio in the United States.

Liam Kelly brings more than 25 years of leadership experience. He served as Chairman, President and Chief Executive Officer of Teleflex Incorporated (NYSE: TFX), a global provider of medical technology products, until January 2026. He led Teleflex as President and Chief Executive Officer from January 2018 and as Chairman of the Board from May 2020. Mr. Kelly joined Teleflex in 2009 and held a series of senior operating roles, including President of EMEA, President, International, President, Americas, and Chief Operating Officer. Before Teleflex, he spent ten years at Hill-Rom Holdings, Inc. in senior management roles. Mr. Kelly is a director of Enovis Corporation (NYSE: ENOV) and holds a Bachelor of Business Studies from the University of Limerick.

“Nyxoah is entering a new chapter, with the United States at the center of our growth strategy. We are very pleased to welcome Liam as our new CEO. He is a seasoned U.S. MedTech executive with a strong track record of scaling organizations, driving commercial performance and creating shareholder value,” said Robert Taub, Chairman of Nyxoah. “On behalf of the Board, I also want to thank Olivier for his leadership over the past seven years and his contribution in bringing Nyxoah from clinical development through FDA approval and into U.S. commercialization.”

“I am incredibly excited to join Nyxoah at this pivotal stage,” said Liam Kelly. “Genio is a truly differentiated technology in the treatment of sleep apnea. The technology has tremendous potential to impact patient lives globally. The U.S. launch is still in its early stages, and the momentum we’re seeing in physician adoption gives me great confidence in what lies ahead. Drawing on my experience at Teleflex building and scaling global businesses, I look forward to working with the Nyxoah team to scale the business and bring Genio to many more OSA patients.”

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study in 2024 and received approval from the FDA in August 2025, with the treatment of CCC patients included in the warning section of our indications for use.

For more information, please visit http://www.nyxoah.com.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the appointment of the Chief Executive Officer and the related leadership transition; the Company’s leadership and organizational structure; the Company’s commercialization strategy in the U.S. market; the Company’s results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah

Rémi Renard, Head of Investor Relations & Corporate Communication
IR@nyxoah.com

Attachment

• ENGLISH_Nyxoah Appoints Liam Kelly as CEO_FINAL